source
- FDA officials stress administration priorities in draft PDUFA VIII commitment letterAt a public meeting on Wednesday, FDA officials presented the proposed commitment letter for the upcoming PDUFA VIII program. The letter reiterates the administration's priorities, reflecting the…
- Skyhawk reports functional gains in Huntington's disease trial of RNA-splicing pillSkyhawk Therapeutics, a Boston biotech backed by Fidelity, released final data from a small mid-stage trial of its once-daily RNA-splicing pill for Huntington's disease. After 15 months, patients…